SCHEMBL24299402

SCHEMBL24299402

CN1CCN(c2ccc3[nH]c(-c4ccc5nc(-c6ccc(OCCCN)cc6)[nH]c5c4)nc3c2)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.71
▸ SMN1; SMN2 Q16637 4/20 0.71
▸ MEN1 O00255 2/20 0.71
▸ MAPT P10636 2/20 0.71
▸ BLM P54132 2/20 0.71
▸ KMT2A Q03164 2/20 0.71
▸ SLCO2B1 O94956 1/20 0.71
▸ GLA P06280 1/20 0.71
▸ RECQL P46063 1/20 0.71
▸ BCL2L1 Q07817 1/20 0.71
▸ SLCO1B3 Q9NPD5 1/20 0.71
▸ TDP1 Q9NUW8 1/20 0.71
▸ SLCO1B1 Q9Y6L6 1/20 0.71
▸ TOP1 P11387 3/20 0.67
▸ TOP2A P11388 3/20 0.67
▸ HPGD P15428 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.60
▸ HRH4 Q9H3N8 1/20 0.57
▸ DRD3 P35462 5/20 0.56
▸ KDM4E B2RXH2 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30522159 1.00 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2MEN1MAPTBLM
SCHEMBL23424055 0.95 ALDH1A1 (0.78) ALDH1A1SMN1; SMN2MEN1MAPTBLM
SCHEMBL23412226 0.93 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2MEN1MAPTBLM
Trifluoroacetic Acid SCHEMBL30522167 0.92 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2MEN1MAPTBLM
SCHEMBL23482780 0.91 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2MEN1MAPTBLM
SCHEMBL25434497 0.91 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2MEN1MAPTBLM
SCHEMBL23424044 0.91 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2MEN1MAPTBLM
SCHEMBL15969230 0.89 ALDH1A1 (0.90) ALDH1A1SMN1; SMN2MEN1MAPTBLM
SCHEMBL14453641 0.88 ALDH1A1 (0.85) ALDH1A1SMN1; SMN2MEN1MAPTBLM
SCHEMBL12944604 0.87 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2MEN1MAPTBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230366045-A1 NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF PROMEGA CORPORATION 2023-11-16 — — US disclosed
US-20230366045-A1 NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF PROMEGA CORPORATION 2023-11-16 — — US disclosed
US-20220064710-A1 NUCLEIC ACID MODIFYING REAGENTS AND USES THEREOF PROMEGA CORPORATION 2022-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230366045-A1 NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF POLM, HNRNPM, POLRMT ALDH1A1 2068/4885SMN1; SMN2 693/4885MEN1 3373/4885
US-20220064710-A1 NUCLEIC ACID MODIFYING REAGENTS AND USES THEREOF POLRMT, NSUN2, ADAR ALDH1A1 2687/4885SMN1; SMN2 1132/4885MEN1 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback